(800) 429-3205

Are You an Eagle Pharmaceuticals Shareholder? Submit Your Information to Learn More About Our Investigation

Berger Montague is currently investigating potential violations of federal securities laws on behalf of shareholders of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX).

Please view our terms of use policy and our privacy policy.

First Name *

Last Name *

Email *

Phone Number *

Address

City

Zip

State

Are you a current or former employee of Eagle Pharmaceuticals, Inc.?

How many shares did you purchase? Please provide ALL transactions.

What dates did you purchase? Please provide ALL dates.

What was the price per share when you purchased? Please provide ALL prices.

Terms of Use *

I agree to the terms of service

Subscribe

I would like to receive updates from Berger Montague

Thank you! Your form has been successfully submitted.

About the Investigation

On November 9, 2023, Eagle disclosed that it would not be able to timely file its quarterly report for the second quarter of 2023 because it required additional time to complete its review of potential adjustments relating to the reporting of sales of PEMFEXY.

On this news, the price of Eagle shares fell $4.16 per share, or 30%, to close at $9.54 per share on November 9, 2023.

Then, on November 29, 2023, Eagle disclosed in a filing with the U.S. Securities and Exchange Commission that Eagle’s President and Chief Executive Officer, Scott Tarriff, was resigning and that the board of directors accepted the resignation “[a]fter consideration of various alternatives, including termination with or without cause.”

On this news, Eagle’s share price fell $2.55, or 31%, to close at $5.68 per share on November 29, 2023.

If you are an Eagle Pharmaceuticals investor and would like to learn more about our investigation, please contact Berger Montague using the form above.